Transcatheter tricuspid valve replacement (TTVR) has emerged as a promising intervention for the treatment of severe tricuspid regurgitation with complex valve morphology. This consensus document provides a comprehensive overview of the current state of orthotopic TTVR, focusing on patient selection, procedural details, and follow-up care.

On March 19, 2025, CMS issued an NCD that covers FDA approved Transcatheter Tricuspid Valve Replacement (TTVR) for the treatment of symptomatic tricuspid regurgitation (TR) under Coverage with Evidence Development (CED), when furnished in accordance with the coverage criteria specified in the NCD.

Jul 12, 2024 · Tricuspid valve repair and tricuspid valve replacement are done to fix a damaged or diseased tricuspid valve. Some tricuspid valve conditions are not well treated with just medicine. Surgery may be needed to reduce symptoms and the risk of complications, such as heart failure.

Mar 25, 2024 · Transcatheter tricuspid valve replacement (TTVR) has been performed off-label as valve-in-valve and valve-in-ring procedures. There are several dedicated tricuspid replacement devices under clinical investigation currently.

Feb 15, 2022 · TTVR is an emerging therapy for patients with severe functional tricuspid regurgitation who are not candidates for transcatheter repair or surgical replacement and would otherwise have an extremely poor prognosis.

Mar 21, 2025 · The U.S. Centers for Medicare & Medicaid Services (CMS) has finalized its decision to cover transcatheter tricuspid valve replacement (TTVR) for the treatment of symptomatic tricuspid regurgitation (TR) on a national level.

TTVR with the Evoque device has been found to be effective in reducing TR, with 97.6% of treated patients having mild TR at follow-up in the TRISCEND trial. 2 Patients treated with TTVR did have increased severe bleeding events (16.9%) and a higher requirement for new permanent pacemaker (13.3%).

Oct 1, 2022 · A myriad of investigational transcatheter tricuspid valve replacement (TTVR) devices have emerged as an alternative to surgery and to address this outstanding need, with promising early results related to safety, efficacy and improvements in patients' functional status and quality of life.

Oct 30, 2024 · Treating severe tricuspid regurgitation (TR) with the Evoque transcatheter tricuspid valve replacement (TTVR) system from Edwards Lifesciences is associated with significant improvements in symptoms and quality of life (QOL) after one year, according to new data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 meeting in ...

Nov 6, 2024 · Interventional cardiologists at Penn Medicine have introduced transcatheter tricuspid valve replacement (TTVR), a novel minimally invasive transcatheter procedure for the treatment of isolated tricuspid valve regurgitation.